Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

Inclusion Criteria: * Histologically proven unresectable MPM of biphasic or sarcomatoid histology * Naïve to chemotherapy or immunotherapy * ECOG PS 0-1 * Expected survival of at least 3 months * Age 18 years or over (there is no upper age limit) * Measurable disease by modified RECIST criteria for MPM for local pleural disease and RECIST 1.1 criteria for metastatic lesions * Written (signed and dated) informed consent and must be capable of co-operating with treatment and follow up * Adequate hematologic, hepatic, and renal function Exclusion Criteria: * Radiotherapy (except for palliative reasons) in the previous two weeks before study treatment * History of unstable cardiac disease * Ongoing toxic manifestations of previous treatments * Symptomatic brain or spinal cord metastases (patients must be stable for \> 1 month post radiotherapy or surgery) * Major thoracic or abdominal surgery from which the patient has not yet recovered.